ERJ open research
THE BEST IN OPEN ACCESS BASIC, TRANSLATIONAL & CLINICAL RESPIRATORY RESEARCH

Early View

Original article

The role of bronchoscopy in patients with SARS-CoV-2 pneumonia

Marisol Arenas-De Larriva, Roberto Martín-DeLeon, Blanca Urrutia Royo, Iker Fernández-Navamuel, Andrés Gimenez Velando, Laura Nuñez García, Carmen Centeno Clemente, Felipe Andreo García, Albert Rafecas Codern, Carmen Fernández-Arias, Virginia Pajares Ruiz, Alfons Torrego Fernández, Olga Rajas, Gorane Iturricastillo, Ricardo Garcia Lujan, Lorena Comeche Casanova, Albert Sánchez-Font, Ricardo Aguilar-Colindres, Roberto Larrosa-Barrero, Ruth García García, Rosa Cordovilla, Ana Núñez-Ares, Andrés Briones-Gómez, Enrique Cases Viedma, José Franco, Javier Cosano Povedano, Manuel Luis Rodríguez-Perálvarez, Jose Joaquin Cebrian Gallardo, Manuel Nuñez Delgado, María Pavón-Masa, Mª del Mar Valdivia Salas, Javier Flandes

Please cite this article as: Arenas-De Larriva M, Martín-DeLeon R, Urrutia Royo B, *et al*. The role of bronchoscopy in patients with SARS-CoV-2 pneumonia. *ERJ Open Res* 2021; in press (https://doi.org/10.1183/23120541.00165-2021).

TITLE PAGE

Manuscript title:

The role of bronchoscopy in patients with SARS-CoV-2 pneumonia

List of authors and affiliations

On behalf of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)

Order	Name/Surname	Degree	Affiliations	Address
1.	Marisol Arenas-De Larriva	MD	Department of Bronchoscopy and Interventional Pulmonology. Hospital Universitario Reina Sofía, IMIBIC	Menéndez Pidal, 14004, Córdoba, Spain.
2.	Roberto Martín-DeLeon	MD	Department of Pulmonology, Hospital Universitario Reina Sofía, IMIBIC.	Menéndez Pidal, 14004, Córdoba, Spain.
3.	Blanca Urrutia Royo	MD	Pulmonary Department. Thorax Clinic Institute. Hospital Universitari Germans Trias i Pujol.	Ctra. de Canyet, s/n, 08916, Badalona, Spain.
4.	Iker Fernández-Navamuel	MD	Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Department, Hospital Fundacion Jimenez Diaz, ISS-FJD, CIBERES.	Reyes Católicos 2, 28040, Madrid, Spain.
5.	Andrés Gimenez Velando	MD	Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Department, Hospital Fundacion Jimenez Diaz, ISS-FJD, CIBERES.	Reyes Católicos 2, 28040, Madrid, Spain.
6.	Laura Nuñez García	MD	Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Department, Hospital Fundacion Jimenez Diaz, ISS-FJD, CIBERES.	Reyes Católicos 2, 28040, Madrid, Spain.
7.	Carmen Centeno Clemente	PhD	Interventional Pulmonology Unit, Pulmonary Department, Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, UAB, IGTP.	Ctra. de Canyet, s/n, 08916, Badalona, Spain.
8.	Felipe Andreo García	PhD	Interventional Pulmonology Unit. Pulmonary Department. Thorax Clinic Institute. Hospital Universitari Germans Trias i Pujol, CIBERES,	Ctra. de Canyet, s/n, 08916, Badalona, Spain.

			UAB, IGTP.	
9.	Albert Rafecas Codern	MD	Respiratory Department, Hospital Santa Creu i Sant Pau.	Sant Quintí, 87, 08041, Barcelona, Spain.
10.	Carmen Fernández-Arias	MD	Respiratory Department, Hospital Santa Creu i Sant Pau.	Sant Quintí, 87, 08041, Barcelona, Spain.
11.	Virginia Pajares Ruiz	MD	Respiratory Department, Hospital Santa Creu i Sant Pau.	Sant Quintí, 87, 08041, Barcelona, Spain.
12.	Alfons Torrego Fernández	MD	Respiratory Department, Hospital Santa Creu i Sant Pau.	Sant Quintí, 87, 08041, Barcelona, Spain.
13.	Olga Rajas	PhD	Interventional Pulmonology Unit, Pulmonology Department, Hospital Universitario de la Princesa, Instituto de Investigación Princesa.	Diego de León, 62. 28006, Madrid, Spain.
14.	Gorane Iturricastillo	MD	Pulmonology Department, Hospital Universitario de la Princesa, Instituto de Investigación Princesa.	Diego de León, 62. 28006, Madrid, Spain.
15.	Ricardo Garcia Lujan	MD	Department of Interventional Pulmonology, Hospital Universitario 12 Octubre and Hospital Univesitario Quirónsalud Madrid.	Avda Córdoba s.n. 28041 Madrid, Spain.
16.	Lorena Comeche Casanova	MD	Department of Pulmonology, Hospital Universitario Quirónsalud Madrid.	Diego de Velázquez, 1, 28223 Pozuelo de Alarcón, Madrid, Spain
17.	Albert Sánchez-Font	PhD	Pulmonology Department, Hospital del Mar, CIBERES, UAB, IMIM (Hospital del Mar Medical Research Institute).	Passeig Marítim, 25-29 08003, Barcelona, Spain.
18.	Ricardo Aguilar-Colindres	MD	Pulmonology Department, Hospital del Mar, CIBERES.	Passeig Marítim, 25-29 08003, Barcelona, Spain.
19.	Roberto Larrosa-Barrero	PhD	Pulmonary Department, Hospital Universitario Clínico San Carlos.	Profesor Martín Lagos, s/n, 28040, Madrid. Spain.
20.	Ruth García García	MD	Interventional Pulmonology Unit. Pulmonary Department. Salamanca University Hospital.	Paseo San Vicente 58-182. 37007. Salamanca, Spain.
21.	Rosa Cordovilla	PhD	Interventional Pulmonology Unit. Pulmonary department. Salamanca University Hospital.	Paseo San Vicente 58-182. 37007. Salamanca, Spain.
22.	Ana Núñez-Ares	PhD	Interventional Pulmonology Unit. Pulmonary Department.	Hermanos Falcó s/n 02007, Albacete, Spain.
23.	Andrés Briones-Gómez	MD	Interventional Pulmonology Unit. Pulmonary Department. Hospital	Fernando Abril Martorell, n.106 46026 Valencia, Spain.

			Universitario y Politécnico La Fe.	
24.	Enrique Cases Viedma	MD	Interventional Pulmonology Unit. Pulmonary Department. Hospital Universitario y Politécnico La Fe.	Fernando Abril Martorell, 106, 46026, Valencia, Spain.
25.	José Franco	PhD	Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute.	Blasco Ibáñez 17, 46010 Valencia, Spain
26.	Javier Cosano Povedano	MD	Bronchoscopy and Interventional Pulmonology Unit. Pulmonology Department. Hospital Universitario Reina Sofía, IMIBIC.	Menéndez Pidal, 14004, Córdoba, Spain.
27.	Manuel Luis Rodríguez-Perálvarez	PhD	Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), CIBERehd, Córdoba (Spain).	Menéndez Pidal, 14004, Córdoba, Spain.
28.	Jose Joaquin Cebrian Gallardo	MD	Department of pulmonology, Agencia sanitaria Costa del Sol.	Autovía A-7 Km 187, 29603 Marbella, Spain.
29.	Manuel Nuñez Delgado	MD	Department of bronchoscopy and Interventional Pulmonology, Hospital Álvaro Cunqueiro, CHUVI.	Estrada Clara Campoamor 3541. 36213, Vigo, Spain.
30.	María Pavón-Masa	PhD	Department of Interventional Pulmonology, Hospital Universitario Virgen Macarena.	Dr. Fedriani, 3, 41009, Sevilla, Spain.
31.	Mª del Mar Valdivia Salas	PhD	Department of Interventional Pulmonology, Hospital Universitario Santa Lucía.	Mezquita s/n, Paraje Los Arcos, 30202, Cartagena, Spain.
32.	Javier Flandes	PhD FCCP	Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Department, Hospital Fundación Jimenez Diaz, ISS-FJD, CIBERES.	Reyes Católicos 2, 28040, Madrid, Spain.

Contact author information: Marisol Arenas De Larriva, MD. Hospital Universitario Reina Sofía. Avda. Menéndez Pidal s/n, Postal code 14004, Córdoba, Spain. Phone: +34 617854692 E-mail: arlam23@hotmail.com

SUMMARY

Bronchoscopy is part of the armamentarium against COVID-19. It allows diagnosis, facilitates mechanical ventilation and provides prognostic information. This information could be used to refine health care pathways in order to improve outcomes.

ABSTRACT

Background: The role of bronchoscopy in coronavirus disease 2019 (COVID-19) is a matter of debate.

Patients and methods: This observational multicenter study aimed to analyze the prognostic impact of bronchoscopic findings in a consecutive cohort of patients with suspected or confirmed COVID-19. Patients were enrolled at 17 hospitals from February to June, 2020. Predictors of in-hospital mortality were assessed by multivariate logistic regression.

Results: A total of 1,027 bronchoscopies were performed in 515 patients (age 61.5±11.2; 73% men), stratified into a clinical suspicion cohort (n=30) and a COVID-19 confirmed cohort (n=485). In the clinical suspicion cohort, the diagnostic yield was 36.7%. In the COVID-19 confirmed cohort, bronchoscopies were predominantly performed in the intensive care unit (n=961; 96.4%) and major indications were: difficult mechanical ventilation (43.7%), mucus plugs (39%) and persistence of radiological infiltrates (23.4%). One hundred forty-seven bronchoscopies were performed to rule out superinfection, and diagnostic yield was 42.9%. There were abnormalities in 91.6% of bronchoscopies, the most frequent being mucus secretions (82.4%), haematic secretions (17.7%), mucus plugs (17.6%), and diffuse mucosal hyperemia

(11.4%). The independent predictors of in-hospital mortality were: older age (Odds ratio [OR]=1.06; p<0.001), mucus plugs as indication for bronchoscopy (OR=1.60; p=0.041), absence of mucosal hyperemia (OR=0.49; p=0.041) and the presence of haematic secretions (OR=1.79; p=0.032).

Conclusions: Bronchoscopy may be indicated in carefully selected patients with COVID-19 to rule out superinfection and solve complications related to mechanical ventilation. The presence of haematic secretions in the distal bronchial tract may be considered a poor prognostic feature in COVID-19.

ABBREVIATIONS (alphabetic order)

- BAL: bronchoalveolar lavage

- BAS: bronchial aspiration

- CT: computed tomography

- CI: confidence interval

- COVID-19: Coronavirus disease 2019

- ICU: Intensive care unit

- IQR: interquartile range

- OR: odds ratio

- RT-PCR: real-time reverse transcriptase polymerase chain reaction assay

- SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

INTRODUCTION

The novel coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originated in Wuhan in the province of Hubei, China, in December 2019[1]. COVID-19 rapidly spread to other countries driven by an increased prevalence of asymptomatic carriers and by the airborne transmission of SARS-CoV-2[2]. In March 2020, COVID-19 was declared a pandemic by the World Health Organization, and since then has challenged health care systems worldwide, making the need to optimize clinical pathways and resource utilization mandatory.

The role of bronchoscopy in COVID-19 is a matter of debate. Among patients with clinical suspicion of COVID-19 with negative nasopharyngeal swab specimen results by real-time reverse transcriptase polymerase chain reaction assay (RT-PCR), bronchoscopy could provide increased sensitivity by obtaining samples from the lower respiratory tract[3]. In patients with severe COVID-19, mainly admitted to the intensive care unit (ICU), bronchoscopy may be required to manage complications such as atelectasis or hemoptysis, to solve issues with mechanical ventilation, and to rule out superinfection. However, bronchoscopy in COVID-19 is not without risks, including disease transmission to the health care staff. Although some scientific societies have issued guidelines in order to reduce heterogeneity in clinical practice[4], the supporting scientific background is scarce and is mainly composed by short series[5-7].

The main endpoint of the present nationwide study was to evaluate the impact of endoscopic findings on outcomes among patients with COVID-19. Secondary outcomes were: a) to describe the indications for bronchoscopy and procedures; b) to analyze the diagnostic yield of bronchoscopy in patients with suspected SARS-CoV-2 pneumonia.

MATERIALS AND METHODS

The "COronavirus & BRonchoscopy in Spain (COBRE)" project is an ambispective multicenter study, which was launched during the first epidemic wave of COVID-19 in Spain. The study was performed according to the principles of the Declaration of Helsinki and aligning with the European Union regulation 2016/679. The study was approved by the Research Ethics Committee of the Hospital Universitario Reina Sofía, Córdoba, Spain (PI 2020/4680).

Study population

Patients were enrolled at 17 secondary and tertiary hospitals in Spain. The recruitment period ranged from February 20th, 2020, when the national authorities informed about community transmission of SARS-CoV-2, until June 30th, 2020, when there was an official declaration of controlled community transmission. Patients admitted to the hospital because of suspected or confirmed COVID-19 who required a bronchoscopy were consecutively included and stratified into two study cohorts:

a) Clinical suspicion cohort: patients with clinical and radiological features of COVID-19 or positive IgM antibody testing, but without confirmation by RT-PCR in two consecutive nasopharyngeal swab specimens, who underwent bronchoscopy for diagnostic purposes.

b) RT-PCR confirmed cohort: patients with SARS-CoV-2 pneumonia confirmed by RT-PCR of nasopharyngeal swab specimens who required a bronchoscopy.

The exclusion criteria for both cohorts were as follows: patients younger than 18 years old; bronchoscopy performed after virological resolution (confirmed by two consecutive RT-PCR

negative tests); interval between COVID-19 confirmation and endoscopic examination longer than 30 days.

Identification of study candidates, data extraction and outcomes

Potential study candidates were screened among patients admitted to the hospital with suspected or confirmed COVID-19. Those patients with compatible clinical symptoms and typical radiological findings[8] with two negative RT-PCR of nasopharyngeal swab specimens could undergo bronchoscopy to obtain a lower respiratory tract specimen and they formed the clinical suspicion cohort. Patients with previous positive RT-PCR of SARS-CoV-2 in nasopharyngeal swab specimens who underwent bronchoscopy to rule out superinfection or for therapeutic purposes formed the RT-PCR-confirmed cohort.

Data was recorded in an anonymized electronic datasheet using the REDCap (Research Electronic Data Capture) platform[9]. Study investigators received online training at baseline to homogenize the data collection, and they were granted access with a unique username/password. All clinical information was extracted from reliable electronic medical data sources. Demographic characteristics and comorbidities (graded with the Charlson comorbidity index as absent if 0-1, mild if 2 or severe if $\geq$3[10]), clinical symptoms, and diagnostic tests of COVID-19 were recorded. Blood tests and radiological features were considered within the 48 hours prior to bronchoscopy. Imaging findings obtained in chest computed tomography (CT) were reported according to the COVID-RADS classification as typical, fairly typical, atypical or normal[11]. Bronchoscopic findings and procedures were also registered. Patients were followed until hospital discharge or death. The main outcome evaluated was in-hospital mortality at 90 days after bronchoscopy.

Sample size calculation

The sample size was calculated using EPIDAT version 4.2 (Xunta de Galicia, Spain). The following assumptions were made to study a theoretical relationship between endoscopic findings and outcomes:

- The prevalence of an endoscopic feature indicating poor prognosis: 20%.

- In-hospital mortality in patients showing an endoscopic feature indicating poor prognosis: 40% (obtained from the upper range of mortality reported in previous series of critically ill patients[12, 13]).

- In-hospital mortality in patients without an endoscopic feature indicating poor prognosis: 25% (obtained from the lower range of mortality reported in previous series of critically ill patients[12, 13]).

- Statistical power: 80%

- Alpha error: 5%

- Incomplete or unavailable data: 5%

Under these premises, the minimum sample size required was 483 patients with RT-PCR-confirmed COVID-19. The study finally comprised 515 patients, including 488 RT-PCR confirmed cases.

Statistical analysis

Categorical variables were described as frequency tables and percentages. Continuous variables were described using mean and standard deviation, except for those with an asymmetric distribution, in which median and interquartile range (IQR) were used. To identify clinical, radiological and endoscopic features associated with in-hospital mortality at 90 days, the first bronchoscopy performed in each patient with RT-PCR-confirmed COVID-19 was considered. Univariate and multivariate logistic regression was used. Variables with a $p<0.30$ in the univariate analysis were entered the initial multivariate model. Endoscopic features with a prevalence ≥5% were also included in the initial multivariate model irrespective of their univariate p value. Non-significant co-variates were removed in a backward stepwise process. All possible interactions were tested. Clinically meaningful variables were also kept in the final model even if they did not reach statistical significance. Kaplan-Meier curves were used for survival analysis, being patients censored at hospital discharge or on October 30th, 2020. The statistical analysis was performed using SPSS version 22.0 (IBM Corp, Armonk, NY). Every hypothesis tested was two-tailed and considered significant if $p <0.05$.

RESULTS

Description of the study population.

A total of 1,027 bronchoscopies were performed in 515 patients (average age 61.5±11.2; 73% men). The clinical suspicion cohort comprised 30 patients (5.8%) while the remaining 485 patients (94.2%) were RT-PCR-confirmed COVID-19, including 86 patients who underwent 147 bronchoscopies to rule out superinfection and 399 patients who required 850 therapeutic bronchoscopies. The clinical characteristics of both cohorts are summarized in table 1. Severe

comorbidity defined as a Charlson score ≥3 was more frequent in the clinical suspicion cohort (33.3%) as compared with the RT-PCR-confirmed cohort (10.1%) ($p<0.001$). The clinical presentation was almost indistinguishable in both cohorts, except for an increased prevalence of cough and myalgias in the RT-PCR-confirmed cohort (74.2% vs 50%, $p=0.004$; and 32.2% vs 13.3%, $p=0.031$, respectively). In the X-ray, bilateral infiltrates predominated in the RT-PCR-confirmed cohort (83.5% vs 60%; $p<0.001$). Admission to the ICU was required in 95.2% of patients in the RT-PCR-confirmed cohort as compared with 26.7% of patients in the clinical suspicion cohort ($p<0.001$).

Clinical suspicion cohort

Bronchoscopies were performed in the bronchoscopy room (50%), ICU (26.7%), respiratory ward (20%) or in the operating room (3.3%). Disposable bronchoscopes were used in 18 procedures (60%) and the preferred access was via nasal (63.3%). Lower respiratory tract specimens obtained were: bronchial aspiration (BAS) (31.6%), bronchoalveolar lavage (BAL) (10.5%), bronchial washing (10.5%) and a combination of BAS and BAL (47.4%). RT-PCR was positive for SARS-CoV-2 in 11 patients (36.7%). Of note, none of the patients undergoing BAS alone had a positive RT-PCR while the diagnostic yield of the remaining specimens ranged from 40% to 60%. Among 19 patients without confirmation of SARS-CoV-2, 5 patients (26.3%) had an alternative diagnosis (Cytomegalovirus, Pneumocystis, Aspergillus and/or Staphylococcus), and 14 patients had no proven microbiological agent in the lower respiratory tract specimens. None of these patients had a subsequent positive test for COVID-19. Patients with and without SARS-CoV-2 confirmation did not show statistical differences regarding age ($p=0.90$), sex distribution ($p=0.70$), smoking history ($p=0.18$) and Charlson comorbidity index ($p=0.47$). Fever, cough, dyspnea and myalgias were distributed homogeneously in both groups

(p=0.61, p=0.70, p=0.13, and p=0.61 respectively). Patients with a SARS-CoV-2 positive RT-PCR were characterized by an increased prevalence of gastrointestinal symptoms (36.4% vs 5.3%; p=0.047). Laboratory parameters including lymphocyte count, D dimer, lactate dehydrogenase, ferritin, C-reactive protein and interleukin-6 were similar in the RT-PCR positive and negative groups (data not shown). The chest X-ray showed interstitial bilateral infiltrates in 63.6% of patients from the SARS-CoV-2 positive group as compared with 31.6% of patients without COVID-19 confirmation (p=0.09). A chest CT was performed in 14 patients within 48 hours prior to bronchoscopy (6 patients with subsequent positive RT-PCR and 8 patients with subsequent negative RT-PCR). There was a typical or fairly typical radiological pattern of COVID-19 in the vast majority of patients (78.6%), without statistical differences between patients with subsequent positive and negative RT-PCR results. There were endoscopic abnormalities in 63.6% of patients with positive COVID-19 RT-PCR vs 36.8% of patients with negative COVID-19 RT-PCR results (p=0.16). The most frequent bronchoscopic findings were: thick mucus secretion (n=9), fluid mucus secretion (n=4) and diffuse mucosal hyperemia (n=3). Admission to the ICU was required in 18.2% of patients with a positive RT-PCR and in 31.6% of patients with a negative RT-PCR (p=0.67). The in-hospital mortality was 18.2% in patients with a SARS-CoV-2 positive RT-PCR and 21.1% in patients with negative RT-PCR (Log rank p=0.47).

RT-PCR-confirmed cohort

The RT-PCR confirmed cohort included 485 hospitalized patients who underwent 997 bronchoscopies (range 1-16 procedures per patient). The number of health care professionals involved in each procedure ranged from 1 to 5. Bronchoscopies were performed predominantly in the ICU (n=961; 96.4%), followed by the COVID-19 ward (n=18; 1.8%), endoscopy room

(n=15; 1.5%) and operating room (n=3; 0.3%). The vast majority of procedures were performed in rooms without negative pressure (90.7%) and using disposable bronchoscopes (94.5%). Regarding ventilatory support, most bronchoscopies were performed with patients under invasive mechanical ventilation (93.2%) and in 66 cases (6.6%) under extra-corporeal membrane oxygenation. The predominant accesses were orotracheal tube (61%) and tracheostomy (35.2%). The patient was in prone position in 55 bronchoscopies (5.5%). The ratio of partial pressure arterial oxygen and fraction of inspired oxygen was 171.9±80.6. Bronchoscopies were indicated to rule out superinfection (14.7%) or for therapeutic purposes (85.3%). Therapeutic indications and endoscopic findings are summarized in table 2. Major indications for bronchoscopy were: complications associated with mechanical ventilation (50%), mucus plugs/atelectasis (46%), persistence or progression of radiological infiltrates (33.4%) and hemoptysis (6%). There were endoscopic abnormalities in 91.6%, the most frequent being mucus secretions (82.4%), mucus plugs (17.6%), haematic secretions/clots (23.7%) and diffuse mucosal hyperemia (11.4%) (figure 1). The most frequent therapy consisted in atelectasis resolution or mucus aspiration (82.3%). Among 147 bronchoscopies performed to rule out superinfection, the microbiological samples were obtained from: BAS (11.6%), BAL (10.9%), bronchial washing (52.5%), and BAS in combination with BAL (21.7%). The diagnostic yield was 42.9%, including 71 microbiological isolations which are detailed as supplementary material.

Impact of endoscopic findings on outcomes

All patients with RT-PCR-confirmed COVID-19, either in nasopharyngeal swab or in lower respiratory tract specimens, were included to evaluate clinical, radiological and endoscopic features associated with mortality (n=496). Univariate and multivariate logistic regression analyses to predict in-hospital mortality at 90 days are shown in Table 3. The independent

predictors of in-hospital mortality were: older age (odds ratio [OR]=1.06; 95%CI 1.03-1.08; p<0.001), mucus plugs as indication for bronchoscopy (OR=1.60; 95%CI 1.02-2.53; p=0.041), absence of diffuse mucosal hyperemia (OR=0.49; 95%CI 0.25-0.97; p=0.041), and the presence of haematic secretions (OR=1.79; 95%CI 1.05-3.05; p=0.032) in the distal bronchial tract. A Charlson score ≥3 was kept in the final model as clinically relevant information. The interval from hospital admission to bronchoscopy behaved as a confounding factor and was controlled in the final model. In the survival analysis, the presence of haematic secretions in the distal bronchial tract was the only endoscopic finding associated with mortality: 53.2% vs 35.7% at 60 days and 61% vs 39.5% at 90 days post-bronchoscopy (Log-rank p=0.038) (figure 2).

DISCUSSION

The present study was carried out in the largest cohort published to date and provides key evidence regarding potential indications for bronchoscopy in patients with suspected or confirmed COVID-19, both for diagnostic or therapeutic purposes. Interestingly, some bronchoscopic findings were independently associated with in-hospital mortality after controlling for potential confounders. This information could be used to refine health care pathways and to reduce heterogeneity in clinical practice, in order to improve outcomes in patients with severe COVID-19.

The diagnosis of SARS-CoV-2 pneumonia is challenging when RT-PCR is negative in conventional nasopharyngeal swabs. Previous studies have suggested that lower respiratory tract specimens could increase sensitivity and allow diagnosis in patients with reduced viral load[3], while others recommend to avoid bronchoscopy for diagnostic purposes[14]. The selection of candidates for diagnostic bronchoscopy is paramount as this is an invasive procedure, not

without risk of complications, and there is also a potential risk of spreading the infection to the medical staff due to the aerosols generated therein[15]. Only patients with high clinical suspicion of COVID-19 and typical radiological findings who test negative in two consecutive nasopharyngeal swabs may be considered for diagnostic bronchoscopy. The diagnostic yield of lower respiratory tract samples in the present study was 36.7% for SARS-CoV-2 (53% if alternative microbiological agents were considered), which was lower than in previous reports (55%-71%)[3, 5]. This may be due to different selection criteria including the number of prior negative swabs and CT findings. In our study, patients with positive and negative results had a similar clinical presentation and laboratory findings, suggestive of high clinical suspicion of COVID-19 in this cohort. Gastrointestinal symptoms could identify a subgroup of candidates for diagnostic bronchoscopy. Another way to optimize the selection of candidates would be to avoid patients with atypical radiological findings[16]. According to our results, bilateral involvement in the chest X-ray and typical or fairly typical findings in the CT as previously defined[11], may help to achieve better selection of patients, thus refining clinical pathways.

International Scientific Societies and expert panels have issued recommendations to safely perform bronchoscopy in patients with suspected or confirmed COVID-19[17-20]. However, statements regarding the optimal approach to obtain microbiological samples are vague. This may explain the heterogeneity in clinical practice, as illustrated in the present study. According to our results, BAS alone should be avoided but other options including BAL, bronchial washing or BAL in combination with BAS, would be equally valid. In contrast, guidelines are broadly homogeneous regarding protocols to protect health care personnel[17, 20, 21]. In brief, bronchoscopies in patients with suspected or confirmed COVID-19 should be performed in negative-pressurized or in adequately ventilated rooms. The involved healthcare personnel may

be experienced and reduced to the minimum (2 or 3 people depending on the procedure). Disposable bronchoscopes are advised. Individual enhanced third-degree protection elements are required (protective glasses or face shield, FFP3 face masks, protective clothing, gloves…). Unfortunately, some of these recommendations are difficult to implement in real clinical practice, particularly in secondary hospitals which were overwhelmed during the peak of the pandemic. Negative-pressurized rooms are anecdotal in ICUs where most therapeutic endoscopies need to be performed. These structural deficiencies should be urgently amended by the health care authorities to protect the medical staff from COVID-19 transmission. In any case, the decision to perform (or not) a bronchoscopy in a patient with COVID-19 should be taken after a careful weighting of potential benefits against the potential risk of disease transmission to healthcare personnel.

Critically ill patients with COVID-19 usually require prolonged mechanical ventilation. Bronchoscopy may help to prevent, diagnose or resolve ventilator-related complications. This is the first multicenter study describing the indications and procedures in this setting. The presence of mucus plugs was the only indication independently associated with worse outcomes (60% increased mortality rates as compared with other indications), although it is tightly related to other indications such as atelectasis, superinfection and difficult mechanical ventilation. It is paramount to optimize ventilation to prevent excess secretions and to perform frequent aspirations through the endotracheal tube[20].

There are well established clinical, analytical and radiological predictors of poor outcomes in patients with COVID-19 including (but not limited to) older age, men, increased comorbidities, lymphopenia, increased D dimer and serum ferritin, and extent of pneumonia in the chest CT[22, 23]. This is the first study sufficiently powered to analyze the impact of bronchoscopic findings

on outcomes among hospitalized patients with COVID-19. The presence of diffuse mucosal hyperemia was associated with reduced in-hospital mortality rates, as it is likely a typical feature of an earlier phase of COVID-19, indicating acute inflammation[24]. This situation may still be reversible with or without anti-inflammatory drugs such as corticosteroids[25]. However, the disappearance of this endoscopic sign under persistent respiratory insufficiency may indicate a poor prognosis. The presence of haematic secretions in the distal bronchial tract was an independent predictor of increased in-hospital mortality. In contrast to diffuse mucosal hyperemia, haematic secretions could translate into irreversible damage of the capillaries and the interstitial/alveolar space, which characterizes the most advanced and severe forms of COVID-19[26-28]. Indeed, the presence of haematic secretions identified a subgroup of very sick patients (16%) with in-hospital mortality above 60%. Further studies focused on this subpopulation are needed to delineate more aggressive and life-saving therapies.

The present study is limited by its ambispective design which precluded a protocolized clinical management of the study population. Although laboratory and radiological assessment of patients with COVID-19 varied among different institutions, making it difficult to extract solid conclusions regarding these parameters, the study adequately captured the heterogeneity in real clinical practice. On the other hand, the number of patients in the clinical suspicion cohort was limited as this indication is uncommon and not accepted by some experts[14]. Finally, a potential relationship between ventilator-derived trauma and some bronchoscopic findings in critically ill patients could not be ruled out.

In conclusion, bronchoscopy is pivotal as part of the armamentarium against COVID-19. In carefully selected patients with clinical and radiological suspicion of SARS-CoV-2 pneumonia who test negative in nasopharyngeal swabs, a lower respiratory tract specimen may provide an

acceptable diagnostic yield, also including the identification of alternative microbiological agents or superinfection. In critically ill patients with COVID-19, bronchoscopy allows removal of mucus plugs and intrabronchial clots, and the resolution of atelectasis, thereby improving mechanical ventilation. Finally, haematic secretions in the respiratory tract and absence of diffuse mucosal hyperemia are poor prognostic features.

TABLES

Table 1. Clinical characteristics of 515 patients admitted to the hospital with suspected or confirmed COVID-19 who required a bronchoscopy.

VARIABLE	Clinical suspicion cohort (n=30)	RT-PCR-confirmed cohort (n=485)	p
Age	59.2 ± 15.5	61.7 ± 10.9	0.390
Sex (women); % (n)	36.7% (11)	26.4% (128)	0.219
Previous medical history			
Diabetes; % (n)	20% (6)	22.5% (109)	0.752
Hypertension; % (n)	36.7% (11)	47.6% (231)	0.243
Cardiovascular; % (n)	13.3% (4)	10.9% (53)	0.684
Bronchopulmonary; % (n)	23.3% (7)	14% (68)	0.161
Neoplasms; % (n)	30% (9)	9.3% (45)	0.002
Charlson comorbidity index			<0.001
0-1	53.3% (16)	77.3% (375)	
2	13.3% (4)	12.6% (61)	
≥3	33.3% (10)	10.1% (49)	
Tobacco consumption; % (n)			0.046
Current smokers	17.9% (5)	6.2% (29)	
Past smokers	17.9% (5)	28% (130)	
Non-smokers	64.2% (18)	65.8% (306)	
Lifetime tobacco consumption (Packs/year); median (IQR)*	21.5 (11.5-46.2)	30 (15-40)	0.988
Immunosuppression			
HIV; % (n)	3.3% (1)	0.8% (4)	0.174
Chemotherapy; % (n)	5 (16.7%)	1% (5)	<0.001
Monoclonal antibodies; % (n)	3.3% (1)	1% (5)	0.304
Calcineurin inhibitors; % (n)	10% (3)	2.1% (10)	0.034
Antimetabolites; % (n)	6.7% (2)	2.1% (10)	0.151
Corticosteroids; % (n)	0% (0)	2.9% (14)	1
Clinical presentation of COVID-19			
Fever; % (n)	76.7% (23)	83.1% (403)	0.366
Dyspnea; % (n)	56.7% (17)	67.4% (327)	0.225
Cough; % (n)	50% (15)	74.2% (360)	0.004
Gastrointestinal symptoms; % (n)	16.7% (5)	23.1% (112)	0.415
Myalgias; % (n)	13.3% (4)	32.2% (156)	0.031
Anosmia/ageusia; % (n)	0 (0%)	6.6% (32)	0.245

Laboratory parameters; median (IQR)			
PaO2/FiO2 ratio**	270 (196-288)	160 (118-216)	0.038
SaO2/FiO2 ratio***	329 (235-387)	184 (132-239)	<0.001
Lymphocyte -count/µl	890 (490-1,540)	700 (540-1,000)	0.115
D dimer -ng/mL	1,113 (577-2,170)	843 (492-1,605)	0.545
Lactate dehydrogenase-U/L	304 (239-507)	450 (340-625)	0.049
Ferritin -ng/mL	589 (359-1,356)	1,275 (648-2,299)	0.107
C-reactive protein -mg/L	36 (12-166)	22 (11-81)	0.438
Interleukin-6 -pg/mL	46 (5-149)	65 (23-130)	0.546
Chest X-ray abnormalities; % (n)			<0.001
Normal	0% (0)	0,4% (2)	
Unilateral interstitial	23.3% (7)	1.6% (8)	
Bilateral interstitial	43.3% (13)	36.7% (178)	
Unilateral consolidation	6.7% (2)	2.9% (14)	
Bilateral consolidation	16.7% (5)	46.8% (227)	
Others	10% (3)	11.5% (56)	
COVID-19 specific therapy			
Azithromycin; % (n)	0% (0)	50.4% (242)	<0.001
Hydroxychloroquine; % (n)	3.3% (1)	75.4% (362)	<0.001
Lopinavir/ritonavir; % (n)	3.3% (1)	54% (259)	<0.001
Remdesivir; % (n)	0% (0)	5% (24)	0.386
Interferon beta; % (n)	3.3% (1)	15.2% (73)	0.104
Anakinra; % (n)	0% (0)	3.8% (18)	0.616
Tocilizumab; % (n)	3.3% (1)	49.2% (236)	<0.001
Antibiotics; % (n)	3.3% (1)	31.7% (152)	<0.001
Corticosteroids; % (n)	3.3% (1)	70.4% (338)	<0.001
Length of hospital stay; median (IQR)	18 (8-28)	38 (22-61)	0.007
Admission in intensive care unit	26.7% (8)	95.2% (456)	<0.001
In-hospital mortality	20% (6)	33.6% (163)	0.123

* Only accounted for current/past smokers; ** PaO2/FiO2 was available in 298 patients; *** SaO2/FiO2 was available in 140 patients who did not have PaO2/FiO2.

IQR: interquartile rante; HIV: human immunodeficiency virus

Table 2. Therapeutic indications and findings in 997 bronchoscopies performed in 485 hospitalized patients with RT-PCR-confirmed SARS-CoV-2 pneumonia.

VARIABLES	% (n)
Indications	
Atelectasis	7% (70)
Mucus plugs	39% (389)
Hemoptysis	6% (60)
Radiological progression	10% (100)
Persistence of radiological infiltrates	23.4% (233)
Difficult mechanical ventilation	43.7% (436)
Impossible weaning from mechanical ventilation	6.3% (63)
Findings	
Normal	8.4% (84)
Diffuse mucosal hyperemia	11.4% (114)
Thick mucus secretion	59.9% (597)
Fluid mucus secretion	22.5% (224)
Mucus plugs	17.6% (175)
Haematic secretions	17.7% (176)
Intrabronchial clots	6% (60)
Location of mucus plugs (n=175)	
Trachea	24% (42)
Main right bronchus	31.4% (55)
Main left bronchus	33.5% (59)
Right superior bronchus	18.3% (32)
Right middle bronchus	24% (42)
Right inferior bronchus	45.1% (79)
Left superior bronchus	16% (28)
Left inferior bronchus	36.6% (64)
Location of intrabronchial clots (n=60)	
Trachea	31.7% (19)
Main right bronchus	55% (33)
Main left bronchus	41.7% (25)
Right superior bronchus	15% (9)
Right middle bronchus	21.7% (13)
Right inferior bronchus	40% (24)
Left superior bronchus	10% (6)
Left inferior bronchus	20% (12)
Therapy	
Aspiration	82.3% (821)
Removal with grasp forceps	1.4% (14)
Cannula placement	0.3% (3)
Bronchial occlusion	0.2% (2)

Cryotherapy	0.1% (1)
Endobronchial selective intubation	0.1% (1)
Intrabronchial drugs	
Saline solution	60.2% (600)
Mesna	5.1% (51)
Hypertonic solution	14.5% (145)
N-acetylcysteine	6% (60)
Hyaluronic acid (+ hypertonic solution)	6.5% (65)
Others	0.9% (9)
Samples	
Bronchial aspiration	43% (429)
Combined bronchial aspiration and bronchoalveolar lavage	24.3% (242)
Bronchoalveolar lavage	5.8% (58)
Bronchial washing	11% (110)
Microbiological agents	
Bacteria	27.2% (271)
Fungi	12.8% (128)
Virus	3.6% (36)

Table 3. Clinical, radiological and endoscopic predictors of in-hospital mortality at 90 days among patients with RT-PCR-confirmed COVID-19 admitted to the hospital who required a first bronchoscopy (n=496). Univariate and multivariate logistic regression analyses were used.

VARIABLES	UNIVARIATE ANALYSIS		MULTIVARIATE ANALYSIS (INITIAL MODEL)		MULTIVARIATE ANALYSIS (FINAL MODEL)	
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Age	1.05 (1.03-1.08)	<0.001	1.05 (1.03-1.08)	<0.001	1.06 (1.03-1.08)	<0.001
Sex (women)	1.14 (0.74-1.74)	0.551	---	---	---	---
Medical History						
Diabetes	0.96 (0.62-1.50)	0.872	---	---	---	---
Hypertension	1.22 (0.84-1.77)	0.292	0.93 (0.59-1.47)	0.768	---	---
Cardiovascular	0.73 (0.39-1.37)	0.333	---	---	---	---
Bronchopulmonary	1.08 (0.64-1.83)	0.767	---	---	---	---
Neoplasms	0.77 (0.40-1.47)	0.427	---	---	---	---
Charlson≥3	1.15 (0.63-2.09)	0.644	1.25 (0.62-2.53)	0.526	1.07 (0.56-2.04)	0.834
Current/past smoking	1.18 (0.79-1.76)	0.403	---	---	---	---
Interval hospital admission to FBC	0.99 (0.98-1.00)	0.053	0.99 (0.98-1.00)	0.163	0.99 (0.98-1.00)	0.076
Clinical presentation						
Fever	0.84 (0.51-1.37)	0.491	---	---	---	---
Dyspnea	1.26 (0.84-1.88)	0.263	1.44 (0.88-2.33)	0.144	---	---
Cough	0.82 (0.54-1.25)	0.361	---	---	---	---
Gastrointestinal	1.05 (0.67-1.62)	0.832	---	---	---	---
Myalgias	1.08 (0.72-1.60)	0.713	---	---	---	---
Laboratory parameters						
Lymphocyte count	1.00 (0.99-1.00)	0.272	1.00 (1.00-1.00)	0.901	---	---
D dimer	1.00 (1.00-1.00)	0.068	1.00 (1.00-1.00)	0.123	---	---
LDH	1.00 (1.00-1.00)	0.543	---	---	---	---
Ferritin	1.00 (1.00-1.00)	0.318	---	---	---	---
Reactive C protein	1.00 (0.99-1.00)	0.151	1.00 (0.99-1.00)	0.206	---	---
Interleukin-6	1.00 (1.00-1.00)	0.498	---	---	---	---
X-ray (bilateral involvement)	1.11 (0.67-1.84)	0.681	---	---	---	---
Indications BC						
Atelectasis	1.02 (0.53-1.96)	0.951	---	---	---	---
Mucus plugs	1.42 (0.94-2.14)	0.092	1.63 (0.97-2.73)	0.063	1.60 (1.02-2.53)	0.041
Hemoptysis	1.26 (0.60-2.67)	0.540	---	---	---	---
Radiological persistence/progression	1.41 (0.91-2.21)	0.123	---	---	---	---
					---	---
Difficult mechanical ventilation*	1.21 (0.83-1.75)	0.319	---	---	---	---
Findings BC						
Mucosal hyperemia	0.81 (0.44-1.50)	0.506	0.45 (0.22-0.94)	0.035	0.49 (0.25-0.97)	0.041
Thick mucus	1.19 (0.82-1.73)	0.365	1.67 (0.99-2.80)	0.051	---	---
Fluid mucus	0.96 (0.61-1.52)	0.964	1.42 (0.75-2.67)	0.281	---	---

Mucus plugs	1.41 (0.89-2.26)	0.142	1.13 (0.63-2.06)	0.673	---	---
Haematic secretions	1.78 (1.09-2.89)	0.020	1.98 (0.63-2.06)	0.028	1.79 (1.05-3.05)	0.032
Clots	1.59 (0.70-3.57)	0.266	1.87 (0.30-2.51)	0.793	---	---

BC: bronchoscopy; LDH: Lactate dehydrogenase; OR: odds ratio; CI: confidence interval. * Includes also impossible weaning from mechanical ventilation

FIGURE LEGENDS

Figure 1. Most representative bronchoscopic findings in patients with RT-PCR-confirmed COVID-19. Panel (A): haematic secretions (white arrows). Panel (B): mucus secretions. Pictures were obtained using disposable bronchoscopes.

Figure 2. Kaplan-Meier curve showing the influence of haematic secretions in the distal bronchial tract on mortality in 496 patients with RT-PCR-confirmed COVID-19 admitted to the hospital.

ACKNOWLEDGEMENTS

The present study was funded by the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR): extraordinary grant PII 2020 for research in COVID-19.

We acknowledge Ms. Donna Pringle for professional English language polishing.

DECLARATION OF INTERESTS

Marisol Arenas-De Larriva has received lecture fees from Ferrer and Novartis.

Manuel Rodríguez-Perálvarez has received lecture fees from Astellas, Novartis and Intercept Pharma.

Javier Cosano has received a travel grant form Izasa Scientific.

Enrique Cases: has received lecture fees from Ambu.

The remaining co-authors have no conflict of interest to disclose.

REFERENCES

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020: 395(10223): 497-506.

2. Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. *Lancet Respir Med* 2020: 8(9): 914-924.

3. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020: 323(18): 1843-1844.

4. Lentz RJ, Colt H. Summarizing societal guidelines regarding bronchoscopy during the COVID-19 pandemic. *Respirology* 2020: 25(6): 574-577.

5. Mondoni M, Sferrazza Papa GF, Rinaldo R, Faverio P, Marruchella A, D'Arcangelo F, Pesci A, Pasini S, Henchi S, Cipolla G, Tarantini F, Giuliani L, Di Marco F, Saracino L, Tomaselli S, Corsico A, Gasparini S, Bonifazi M, Zuccatosta L, Saderi L, Pellegrino G, Davi M, Carlucci P, Centanni S, Sotgiu G. Utility and safety of bronchoscopy during the SARS-CoV-2 outbreak in Italy: a retrospective, multicentre study. *Eur Respir J* 2020: 56(4): 2002767.

6. Torrego A, Pajares V, Fernandez-Arias C, Vera P, Mancebo J. Bronchoscopy in Patients with COVID-19 with Invasive Mechanical Ventilation: A Single-Center Experience. *Am J Respir Crit Care Med* 2020: 202(2): 284-287.

7. Chang SH, Jiang J, Kon ZN, Williams DM, Geraci T, Smith DE, Cerfolio RJ, Zervos M, Bizekis C. Safety and Efficacy of Bronchoscopy in Critically Ill Patients with Coronavirus Disease 2019. *Chest* 2021: 159(2): 870-872.

8. Kanne JP, Bai H, Bernheim A, Chung M, Haramati LB, Kallmes DF, Little BP, Rubin G, Sverzellati N. COVID-19 Imaging: What We Know Now and What Remains Unknown. *Radiology* 2021: 204522.

9. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, Consortium RE. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019: 95: 103208.

10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987: 40(5): 373-383.

11. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies. *Eur Radiol* 2020: 30(9): 4930-4942.

12. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, Network C-LI. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020: 323(16): 1574-1581.

13. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, Kritek PA, West TE, Luks A, Gerbino A, Dale CR, Goldman JD, O'Mahony S, Mikacenic C. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J Med* 2020: 382(21): 2012-2022.

14. Ora J, Puxeddu E, Cavalli F, Giorgino FM, Girolami A, Chiocchi M, Sergiacomi G, Federici M, Rogliani P. Does bronchoscopy help the diagnosis in COVID-19 infection? *Eur Respir J* 2020: 56(2): 2001619.

15. Jackson T, Deibert D, Wyatt G, Durand-Moreau Q, Adisesh A, Khunti K, Khunti S, Smith S, Chan XHS, Ross L, Roberts N, Toomey E, Greenhalgh T, Arora I, Black SM, Drake J, Syam N, Temple R, Straube S. Classification of aerosol-generating procedures: a rapid systematic review. *BMJ Open Respir Res* 2020: 7(1).

16. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology* 2020: 296(2): E32-E40.

17. Wahidi MM, Shojaee S, Lamb CR, Ost D, Maldonado F, Eapen G, Caroff DA, Stevens MP, Ouellette DR, Lilly C, Gardner DD, Glisinski K, Pennington K, Alalawi R. The Use of Bronchoscopy During the Coronavirus Disease 2019 Pandemic: CHEST/AABIP Guideline and Expert Panel Report. *Chest* 2020: 158(3): 1268-1281.

18. Luo F, Darwiche K, Singh S, Torrego A, Steinfort DP, Gasparini S, Liu D, Zhang W, Fernandez-Bussy S, Herth FJF, Shah PL. Performing Bronchoscopy in Times of the COVID-19 Pandemic: Practice Statement from an International Expert Panel. *Respiration* 2020: 99(5): 417-422.

19. Steinfort DP, Herth FJF, Irving LB, Nguyen PT. Safe performance of diagnostic bronchoscopy/EBUS during the SARS-CoV-2 pandemic. *Respirology* 2020: 25(7): 703-708.

20. Yang H, Chen H, Gao B, Xiong W, Zhang X, Hogarth DK, Sun J, Ke M, Herth FJF. Expert panel consensus statement on the applications and precaution strategies of bronchoscopy in patients with COVID-19. *Endosc Ultrasound* 2020: 9(4): 211-219.

21. Cordovilla R, Alvarez S, Llanos L, Nunez Ares A, Cases Viedma E, Diaz-Perez D, Flandes J. SEPAR and AEER consensus recommendations on the Use of Bronchoscopy and Airway Sampling in Patients with Suspected or Confirmed COVID-19 Infection. *Arch Bronconeumol* 2020: 56 Suppl 2: 19-26.

22. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020: 395(10229): 1054-1062.

23. Colombi D, Villani GD, Maffi G, Risoli C, Bodini FC, Petrini M, Morelli N, Anselmi P, Milanese G, Silva M, Sverzellati N, Michieletti E. Qualitative and quantitative chest CT parameters as predictors of specific mortality in COVID-19 patients. *Emerg Radiol* 2020: 27(6): 701-710.

24. Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. *Respir Med* 2020: 176: 106239.

25. Cano EJ, Fuentes XF, Campioli CC, O'Horo JC, Saleh OA, Odeyemi Y, Yadav H, Temesgen Z. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. *Chest* 2020: S0012-3692(20)35107-2.

26. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med* 2020: 8(7): 681-686.

27. Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, Najafian B, Deutsch G, Lacy JM, Williams T, Yarid N, Marshall DA. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. *Lancet* 2020: 396(10247): 320-332.

28. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, Bassetti S, Leuppi JD, Cathomas G, Tolnay M, Mertz KD, Tzankov A. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. *Histopathology* 2020: 77(2): 198-209.


A
B



Group; Number at risk	30 days	60 days	90 days
With bloody secretions	50	10	5
Without bloody secretions	168	57	24

SUPPLEMENTARY MATERIAL

Supplementary table. Microbiological agents found in lower respiratory tract specimens in 78 patients with PCR-confirmed COVID-19 and superinfection.

Microorganism	Microbiological agent	Number of isolations (%)
Bacteria	Pseudomonas aeruginosa	16 (22.6%)
	Klebsiella pneumoniae	7 (10%)
	Staphylococcus aureus	6 (8.5%)
	Enterococcus faecium	3 (4.2%)
	Klebsiella aerogenes	2 (2.8%)
	Enterobacter cloacae	2 (2.8%)
	Streptococcus angiosus	2 (2.8%)
	Escherichia coli	2 (2.8%)
	Actinomyces spp	1 (1.4%)
	Enterococcus faecalis	1 (1.4%)
	Citrobacter freundii	1 (1.4%)
	Prevotella melaninogenica	1 (1.4%)
	Veillonella parvula	1 (1.4%)
	Achromobacter xylosoxidans	1 (1.4%)
	Streptococcus viridans	1 (1.4%)
	Streptococcus constellaus	1 (1.4%)
	Serratia marcescens	1 (1.4%)
	Acinetobacter baumannii	1 (1.4%)
	Mycobacterium tuberculosis	1 (1.4%)
Virus	Herpes simplex I	8 (11.3%)
	Cytomegalovirus	2 (2.8%)
	Rhinovirus	1 (1.4%)
Fungi	Candida albicans	4 (5.6%)
	Aspergillus fumigatus	2 (2.8%)
	Candida auris	1 (1.4%)
	Candida krusei	1 (1.4%)
	Candida parapsilosis	1 (1.4%)